

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

**VOLUNTARY ANNOUNCEMENT
COMPLETION OF FULL COURSE OF VACCINATION IN SUBJECTS OF
PHASE III CLINICAL TRIAL OF
23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

To date, the randomized, blinded and comparable vaccine-controlled Phase III clinical trial of the Group’s 23-valent pneumococcal polysaccharide vaccine has completed the full course of vaccination of all of the 1,920 enrolled healthy subjects aged two years old and above at two sites in Sichuan Province and one site in Shandong Province. The clinical trial will proceed to serology testing and statistical unblinding work.

The Phase I clinical trial of the 23-valent pneumococcal polysaccharide vaccine had been initiated in December 2021 at the Centre for Disease Control and Prevention of Nanbu County, Sichuan Province. The results of the completed Phase I clinical trial to date have demonstrated good safety profile and immunogenicity of the vaccine.

The 23-valent pneumococcal polysaccharide vaccine is indicated for the prevention of invasive pneumococcal diseases in age groups above two years old, especially those above 60 years old. The vaccine contains 23 types of pneumococcal serotype polysaccharide antigens, which can prevent pneumonia, meningitis, otitis media and bacteremia caused by pneumococcal infections, covering nearly 90% of the serotypes most commonly reported to cause pneumococcal diseases. The Group has completed the construction of the production workshops for this vaccine with a designed manufacturing capacity of 15 million doses.

Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
AIM Vaccine Co., Ltd.

Mr. Yan ZHOU

*Chairman of the Board, Executive Director
and Chief Executive Officer*

Hong Kong, October 8, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.